Companies / Sionna Therapeutics, Inc. / Activity
Activity — Sionna Therapeutics, Inc.
33 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Apr 15, 2026 | Thompson Peter A. Director | Sell | Common Stock | $10.53M | -236K -6.77% | 3,247,025 7.18% of shares | medium |
| Apr 15, 2026 | Orbimed Advisors LLC Director | Sell | Common Stock | $10.53M | -236K -6.77% | 3,247,025 7.18% of shares | medium |
| Apr 16, 2026 | Thompson Peter A. Director | Sell | Common Stock | $10.29M | -227K -6.99% | 3,020,119 6.68% of shares | medium |
| Apr 16, 2026 | Orbimed Advisors LLC Director | Sell | Common Stock | $10.29M | -227K -6.99% | 3,020,119 6.68% of shares | medium |
| Jan 22, 2026 | Tpg Gp a, LLC 10% owner | Sell | Common Stock | $10.00M | -250K -3.71% | 6,494,962 14.37% of shares | medium |
| May 11, 2026 | Thompson Peter A. Director | Sell | Common Stock | $8.53M | -185K -6.46% | 2,671,822 5.91% of shares | medium |
| May 11, 2026 | Orbimed Advisors LLC Director | Sell | Common Stock | $8.53M | -185K -6.46% | 2,671,822 5.91% of shares | medium |
| May 8, 2026 | Thompson Peter A. Director | Sell | Common Stock | $2.66M | -60K -2.05% | 2,856,461 6.32% of shares | medium |
| May 8, 2026 | Orbimed Advisors LLC Director | Sell | Common Stock | $2.66M | -60K -2.05% | 2,856,461 6.32% of shares | medium |
| Apr 17, 2026 | Thompson Peter A. Director | Sell | Common Stock | $2.34M | -52K -1.73% | 2,967,722 6.56% of shares | medium |
| Apr 17, 2026 | Orbimed Advisors LLC Director | Sell | Common Stock | $2.34M | -52K -1.73% | 2,967,722 6.56% of shares | medium |
| May 7, 2026 | Thompson Peter A. Director | Sell | Common Stock | $2.17M | -49K -1.64% | 2,916,228 6.45% of shares | medium |
| May 7, 2026 | Orbimed Advisors LLC Director | Sell | Common Stock | $2.17M | -49K -1.64% | 2,916,228 6.45% of shares | medium |
| Apr 14, 2026 | Thompson Peter A. Director | Sell | Common Stock | $2.13M | -48K -1.35% | 3,482,888 7.70% of shares | medium |
| Apr 14, 2026 | Orbimed Advisors LLC Director | Sell | Common Stock | $2.13M | -48K -1.35% | 3,482,888 7.70% of shares | medium |
| Feb 3, 2026 | Orbimed Advisors LLC Director | Sell | Common Stock | $1.30M | -29K -0.82% | 3,530,702 7.81% of shares | medium |
| Feb 3, 2026 | Thompson Peter A. Director | Sell | Common Stock | $1.30M | -29K -0.82% | 3,530,702 7.81% of shares | medium |
| Mar 5, 2026 | Fitzpatrick Jennifer Executive | Sell | Common Stock | $347.0K | -10K -100.00% | 0 0.00% of shares | medium |
| Apr 18, 2026 | Thompson Peter A. Director | Sell | Common Stock | $131.2K | -3K -0.10% | 2,964,774 6.56% of shares | medium |
| Apr 18, 2026 | Orbimed Advisors LLC Director | Sell | Common Stock | $131.2K | -3K -0.10% | 2,964,774 6.56% of shares | medium |
| Feb 2, 2026 | Orbimed Advisors LLC Director | Sell | Common Stock | $84.2K | -2K -0.05% | 3,559,765 7.87% of shares | low |
| Feb 2, 2026 | Thompson Peter A. Director | Sell | Common Stock | $84.2K | -2K -0.05% | 3,559,765 7.87% of shares | low |
| Mar 5, 2026 | Fitzpatrick Jennifer Executive | Exercise | Common Stock | $62.6K | +10K | 10,250 0.02% of shares | low |
| May 27, 2026 | Thompson Peter A. Director | Sell | Common Stock | $4.5K | -101 -0.00% | 2,671,721 5.91% of shares | low |
| May 27, 2026 | Orbimed Advisors LLC Director | Sell | Common Stock | $4.5K | -101 -0.00% | 2,671,721 5.91% of shares | low |
| Jun 17, 2026 | Thompson Peter A. Director | Grant | Non-Qualified Stock Option (right to buy) | — | +17K | 17,340 0.04% of shares | low |
| Jun 17, 2026 | RA Capital Management, L.P. Director | Grant | Non-Qualified Stock Option (right to buy) | — | +17K | 17,340 0.04% of shares | low |
| Mar 5, 2026 | Fitzpatrick Jennifer Executive | Exercise | Non-Qualified Stock Option (right to buy) | — | -10K -16.75% | 50,935 0.11% of shares | low |
| Jan 2, 2026 | Beer Caroline Stark Executive | Grant | Non-Qualified Stock Option (right to buy) | — | +139K | 139,340 0.31% of shares | low |
| Jan 2, 2026 | Fitzpatrick Jennifer Executive | Grant | Non-Qualified Stock Option (right to buy) | — | +103K | 103,140 0.23% of shares | low |
| Jan 2, 2026 | McKee Charlotte Executive | Grant | Non-Qualified Stock Option (right to buy) | — | +156K | 155,700 0.34% of shares | low |
| Jan 2, 2026 | Ridloff Elena Executive | Grant | Non-Qualified Stock Option (right to buy) | — | +165K | 165,440 0.37% of shares | low |
| Jan 2, 2026 | Cloonan Michael CEO | Grant | Non-Qualified Stock Option (right to buy) | — | +436K | 436,100 0.96% of shares | low |